These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9663365)

  • 1. Effects of beano on the tolerability and pharmacodynamics of acarbose.
    Lettieri JT; Dain B
    Clin Ther; 1998; 20(3):497-504. PubMed ID: 9663365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.
    Santeusanio F; Compagnucci P
    Drug Saf; 1994 Dec; 11(6):432-44. PubMed ID: 7727053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance].
    Gendeleka GF
    Lik Sprava; 1997; (6):105-7. PubMed ID: 9589946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic relationships of Acarbose.
    Salvatore T; Giugliano D
    Clin Pharmacokinet; 1996 Feb; 30(2):94-106. PubMed ID: 8906894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus.
    Balfour JA; McTavish D
    Drugs; 1993 Dec; 46(6):1025-54. PubMed ID: 7510610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acarbose: an alpha-glucosidase inhibitor.
    Martin AE; Montgomery PA
    Am J Health Syst Pharm; 1996 Oct; 53(19):2277-90; quiz 2336-7. PubMed ID: 8893066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB; Bray GA
    Am J Med; 1995 May; 98(5):443-51. PubMed ID: 7733122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year acarbose treatment raises fasting serum acetate in diabetic patients.
    Wolever TM; Radmard R; Chiasson JL; Hunt JA; Josse RG; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Diabet Med; 1995 Feb; 12(2):164-72. PubMed ID: 7743764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. alpha-Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects.
    Toeller M
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():31-5. PubMed ID: 8001625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance.
    Kentrup H; Bongers H; Spengler M; Kusenbach G; Skopnik H
    Eur J Pediatr; 1999 Jun; 158(6):455-9. PubMed ID: 10378391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Asian Acarbose Study Group.
    Chan JC; Chan KW; Ho LL; Fuh MM; Horn LC; Sheaves R; Panelo AA; Kim DK; Embong M
    Diabetes Care; 1998 Jul; 21(7):1058-61. PubMed ID: 9653595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with acarbose: results of a Canadian multicentre study.
    Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
    Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acarbose in treatment of type II diabetes mellitus: a double-blind, crossover, placebo-controlled trial.
    Soonthornpun S; Rattarasarn C; Thamprasit A; Leetanaporn K
    J Med Assoc Thai; 1998 Mar; 81(3):195-200. PubMed ID: 9623011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with acarbose as first line therapy in NIDDM.
    Fölsch UR
    Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
    Domke A; Willms B
    Med Klin (Munich); 1994 Apr; 89(4):187-92. PubMed ID: 8015532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone.
    Hanefeld M; Fischer S; Schulze J; Spengler M; Wargenau M; Schollberg K; Fücker K
    Diabetes Care; 1991 Aug; 14(8):732-7. PubMed ID: 1954810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New horizons in diabetes therapy--alpha glucosidase inhibitors.
    Jawad F
    J Pak Med Assoc; 1994 Mar; 44(3):59-60. PubMed ID: 8040998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.